Biogen shares drop after revenue, earnings forecast fall short of Street expectations
Biogen expects “minimal” revenue this year from its Alzheimer’s treatment initially hailed as potentially a breakthrough drug, but one with an eye-popping price tag that drew immediate criticism from doctors and patient advocates.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed